Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep 19:56:101502.
doi: 10.1016/j.gore.2024.101502. eCollection 2024 Dec.

Treatment of recurrent ovarian germ cell tumours: Is there a role for immune checkpoint inhibitors?

Laurence Bernard  1
Affiliations
Review

Treatment of recurrent ovarian germ cell tumours: Is there a role for immune checkpoint inhibitors?

Laurence Bernard. Gynecol Oncol Rep. .

Abstract

Ovarian germ cell tumours predominantly affect young women and have an excellent prognosis. While most contemporary papers concentrate on reducing treatment morbidity and preserving fertility, some women still succumb to refractory or recurrent OGCTs. Despite the significant impact of immune checkpoint inhibitors (ICIs) on many tumors, no case of a chemo-resistant ovarian germ cell tumour successfully treated with immunotherapy has been reported. In testicular cancer, only a few cases of partial response or stable disease to ICIs have been described. PD-L1 expression does not predict response, but microsatellite instability status may serve as a potential biomarker. MSI testing should be performed on a recurrent tumour sample as MSI status may evolve during treatment.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Adra N., Abonour R., Althouse S.K., Albany C., Hanna N.H., Einhorn L.H. High-dose chemotherapy and autologous peripheral-blood stem-cell transplantation for relapsed metastatic germ cell tumors: The Indiana university experience. J. Clin. Oncol. 2017;35:1096–1102. doi: 10.1200/JCO.2016.69.5395. - DOI - PMC - PubMed
    1. Adra N., Einhorn L.H., Althouse S.K., Ammakkanavar N.R., Musapatika D., Albany C., Vaughn D., Hanna N.H. Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. Ann. Oncol. off. J. Eur. Soc. Med. Oncol. 2018;29:209–214. doi: 10.1093/annonc/mdx680. - DOI - PubMed
    1. K. Alwosaibai, Z.I. Alruwaii, M. Mashhour, F.M. Almsned, R. Asraf, W. Alrsheedy, A. Alessa, H. Almohanna, W. Selwi, F. Azam, Dysgerminoma germ cell tumors exhibit high expression of PD-L1 and are associated with high levels of tumor-infiltrating lymphocytes and a good patient prognosis, (2024). Doi: 10.21203/rs.3.rs-4464501/v1.
    1. Chi D., Berchuck A., Dizon D.S., Yashar C.M. 7th edition, Wolters Kluwer; 2017. Principles and Practice of Gynecologic Oncology -
    1. Chi E.A., Schweizer M.T. Durable Response to Immune Checkpoint Blockade in a Platinum-Refractory Patient With Nonseminomatous Germ Cell Tumor. Clin. Genitourin. Cancer. 2017;15:e855–e857. doi: 10.1016/j.clgc.2017.04.005. - DOI - PubMed

LinkOut - more resources